The Sympathetic Nervous System in Chronic Kidney Disease
暂无分享,去创建一个
M. Böhm | R. Schmieder | F. Mahfoud | D. Linz | S. Ewen | C. Ukena | M. Böhm
[1] P. Blankestijn,et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. , 2001, Journal of the American Society of Nephrology : JASN.
[2] F. Mahfoud. Renale Sympathikusdenervation bei arterieller Hypertonie – Pro , 2012, Deutsche Medizinische Wochenschrift.
[3] I. Reid. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.
[4] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[5] M. Bots,et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. , 2009, Journal of nephrology.
[6] P. Blankestijn,et al. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] J. Zanzinger. Role of nitric oxide in the neural control of cardiovascular function. , 1999, Cardiovascular research.
[8] R. Bigazzi,et al. Altered norepinephrine turnover in the brain of rats with chronic renal failure. , 1994, Journal of the American Society of Nephrology : JASN.
[9] M. Koss,et al. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] M. Esler,et al. Sympathetic activation in chronic renal failure. , 2009, Journal of the American Society of Nephrology : JASN.
[11] C. Zoccali,et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.
[12] E. Schiffrin,et al. Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.
[13] G. Bakris,et al. Hypertension awareness, treatment, and control in chronic kidney disease. , 2008, The American journal of medicine.
[14] V. Somers,et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure , 2007, Journal of hypertension.
[15] Alexander G Logan,et al. Relationship Between Overnight Rostral Fluid Shift and Obstructive Sleep Apnea in Drug-Resistant Hypertension , 2010, Hypertension.
[16] L. Rump,et al. [Pathophysiology of hypertension: what's new?]. , 2006, Herz.
[17] Guido Grassi,et al. Sympathetic nervous system: role in hypertension and in chronic kidney disease , 2012, Current opinion in nephrology and hypertension.
[18] K. Rahn,et al. Sympathetic Nerve Activity in End-Stage Renal Disease , 2002, Circulation.
[19] R. Minutolo,et al. Resistant Hypertension in Nondialysis Chronic Kidney Disease , 2013, International journal of hypertension.
[20] R. Schmieder,et al. Tonic Postganglionic Sympathetic Inhibition Induced by Afferent Renal Nerves? , 2012, Hypertension.
[21] Giuseppe Mancia,et al. Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure , 2011, Hypertension.
[22] C. Bergamaschi,et al. Rostral ventrolateral medulla : A source of sympathetic activation in rats subjected to long-term treatment with L-NAME. , 1999, Hypertension.
[23] Dominik Linz,et al. Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2012, Hypertension.
[24] G. Mancia,et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[25] Symplicity Htn Investigators,et al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.
[26] V. Campese,et al. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. , 2002, American journal of hypertension.
[27] Xiaoqiang Yao,et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. , 2005, The Journal of clinical investigation.
[28] E. Ritz,et al. Glomerulosclerosis and progression: Effect of subantihypertensive doses of α and βblockers , 2001 .
[29] V. Campese,et al. Renal afferent denervation prevents hypertension in rats with chronic renal failure. , 1995, Hypertension.
[30] S. Genovesi,et al. Renal chemoreceptors. , 1981, Journal of the autonomic nervous system.
[31] V. Campese,et al. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. , 1997, Kidney international.
[32] G. Desir,et al. Catecholamines Regulate the Activity, Secretion, and Synthesis of Renalase , 2008, Circulation.
[33] 김희진,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis , 2012 .
[34] H. Seller,et al. Neuronal nitric oxide reduces sympathetic excitability by modulation of central glutamate effects in pigs. , 1997, Circulation research.
[35] S. Achenbach,et al. Renal sympathetic denervation does not aggravate functional or structural renal damage. , 2013, Journal of the American College of Cardiology.
[36] P. Blankestijn,et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. , 1999, The New England journal of medicine.
[37] F. Mahfoud. [Renal denervation in hypertension - pro]. , 2012, Deutsche medizinische Wochenschrift.
[38] M. Koss,et al. A limited renal injury may cause a permanent form of neurogenic hypertension. , 1998, American journal of hypertension.
[39] P. Blankestijn,et al. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. , 2002, Journal of the American College of Cardiology.
[40] G. Beck,et al. β-Blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] R. Converse,et al. Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.
[42] H. Krum,et al. Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.
[43] S. Schreiber,et al. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. , 1993, Circulation research.
[44] P. Golino,et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. , 2003, Journal of the American College of Cardiology.
[45] V. Oberhauser,et al. Moxonidine treatment of hypertensive patients with advanced renal failure , 2003, Journal of hypertension.
[46] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[47] J. Stegbauer,et al. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. , 2005, Cardiovascular research.
[48] V. Campese. Neurogenic factors and hypertension in chronic renal failure. , 1997, Journal of nephrology.
[49] E. Herzog,et al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Meta- , 2013 .
[50] M. Ishii,et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. , 1983, Hypertension.
[51] C. Zoccali,et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. , 2002, Kidney international.
[52] E. Ritz,et al. Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. , 2001, Kidney international.
[53] M. Uder,et al. Renal Denervation in a Hypertensive Patient With End‐Stage Renal Disease and Small Arteries: A Direction for Future Research , 2012, Journal of clinical hypertension.
[54] W. J. Elliott,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .
[55] W. Fang,et al. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. , 2010, European journal of internal medicine.
[56] G. Dibona. Physiology in perspective: The Wisdom of the Body. Neural control of the kidney. , 2005, American journal of physiology. Regulatory, integrative and comparative physiology.
[57] V. Campese,et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. , 2004, American journal of physiology. Heart and circulatory physiology.
[58] D. Morgan,et al. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[59] B. Conrad,et al. Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis: A 3-Year Follow-Up Study , 2000, Circulation.
[60] R. Katholi,et al. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. , 1984, Journal of hypertension.
[61] D. Marcelli,et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. , 2010, Journal of the American College of Cardiology.
[62] R. Victor,et al. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. , 1999, Hypertension.
[63] G. Dibona. Neural control of the kidney: past, present, and future. , 2003, Hypertension.
[64] P. Blankestijn,et al. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease , 2011, Journal of hypertension.
[65] M. Uder,et al. Vascular and renal hemodynamic changes after renal denervation. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[66] P. Blankestijn,et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.
[67] S. Carlson,et al. Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action , 2008, Current hypertension reports.
[68] G. Bakris,et al. Beta blockers in the management of chronic kidney disease. , 2006, Kidney international.
[69] P. Blankestijn,et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis , 2007, Journal of hypertension.
[70] W. Weichert,et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. , 2007, The American journal of pathology.
[71] H. Krum,et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. , 2013, International journal of cardiology.
[72] Carmine Zoccali,et al. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease , 2008, Current opinion in nephrology and hypertension.
[73] L. Rump,et al. [Pathophysiology of hypertension: what's new?]. , 2006, Herz.